Lucy Scientific Discovery, Inc.

General Information
Business:

(Lucy Scientific Discovery Inc. filed an S-1/A dated Nov. 14, 2022, in which it deleted the warrants from its IPO – now a stock-only deal with IPO proceeds estimated at about $10 million. In the Nov. 14, 2022, filing with the SEC, Lucy Scientific Discovery also switched sole book-runner – to WestPark Capital – from EF Hutton. Lucy Scientific Discovery filed its S-1 on Jan. 21, 2022; it submitted confidential IPO documents to the SEC on Sept. 27, 2021.)

We are an early-stage psychotropics contract manufacturing company focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. (Incorporated in British Columbia)

In August 2021, Health Canada’s Office of Controlled Substances granted us a Controlled Drugs and Substances Dealer’s Licence under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s Licence. 

In Canada, the psychedelic compounds that we are approved to produce under our Dealer’s Licence, psilocybin, psilocin, lysergic acid diethylamide, or LSD, N,N-Dimethyltryptamine, or N,N-DMT, and 3,4-Methylenedioxymethamphetamine, or MDMA, and 4-Bromo-2,5-Dimethoxybenzeneethanamine, or 2C-B, are regulated under the Controlled Drugs and Substances Act, or CDSA. Certain psychedelic substances, including psilocybin, psilocin, mescaline and DMT, are classified as Schedule III drugs and the CDSA prohibits the possession of a Schedule III drug absent authorization under the CDSA or a related regulation, and it is illegal to possess Schedule III substances without a prescription.

In the United States, these substances are classified under the Controlled Substances Act (21 U.S.C. § 811), or the CSA, and the Controlled Substances Import and Export Act, or the CSIEA, and as such, medical and recreational use is illegal under the U.S. federal laws. 

An increasing number of the leading universities, hospitals and other public, private, and government institutions have launched research programs and are conducting clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances, including the John Hopkins Center for Psychedelic and Consciousness Research at Johns Hopkins University, the Imperial College of London Centre for Psychedelic Research, the Center for the Science of Psychedelics at the University of California, Berkeley, the Depression Evaluation Service at Columbia University, the Center for Psychedelic Psychotherapy and Trauma Research at the Icahn School of Medicine at Mount Sinai Health System, New York City’s largest academic medical system, and the Center for the Neuroscience of Psychedelics at Massachusetts General Hospital, among many others.

To address mounting demands for alternative therapies incorporating the use of psychedelics and other psychotropics, we intend to leverage our 25,000-square-foot facility ear Victoria, British Columbia, for research, development, and large-scale production of high-quality biological raw materials, APIs, and finished biopharmaceutical products. 

**Note: Revenue and net loss figures are in U.S. dollars for the year that ended June 30, 2022.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 0
Founded: 2017
Contact Information
Address 301-1321 Blanshard Street Victoria, British Columbia V8W 0B6 Canada
Phone Number (778) 410-5195
Web Address https://www.lucyscientific.com/
View Prospectus: Lucy Scientific Discovery, Inc.
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-5.86 mil (last 12 months)
IPO Profile
Symbol LSDI
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $10.0 mil
Manager / Joint Managers WestPark Capital
CO-Managers
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change